相关实验视频

Updated: Jun 10, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

汽车巨:突破细胞免疫疗法的新领域

Ting Huang^1,2, Chenqi Bei^1,2, Zhenhua Hu¹

¹Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, China.

Frontiers in cell and developmental biology

|October 18, 2024

概括

化学抗原受体巨细胞 (CAR-Ms) 提供了一个有前途的新型细胞免疫疗法. CAR-Ms有效向固体瘤,克服CAR-T细胞的局限性,改善癌症治疗.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
生物技术是生物技术.

背景情况:

化学抗原受体 (CAR) T细胞疗法在血液癌症中取得了成功,但在对抗固体瘤方面面临挑战.
固体瘤具有复杂的微环境,限制了CAR-T细胞的疗效.
需要新的细胞免疫疗法,改善固体瘤的疗效和安全性.

研究的目的:

审查癌症免疫治疗中CAR-巨细胞 (CAR-M) 技术的最新进展.
突出CAR-Ms的潜力,克服CAR-T细胞在治疗固体瘤中的局限性.
讨论工程策略,临床前证据,挑战和CAR-M疗法的未来方向.

主要方法:

审查临床前研究和CAR-M技术的最新进展.
分析CAR-M工程策略以提高抗瘤疗效.
对基于CAR的免疫疗法相关的巨细胞性质的评估.

主要成果:

CAR-Ms有效地向和破坏瘤细胞,包括在具有挑战性的瘤微环境中.
CAR-Ms 显示出直接的细胞毒性,并增强其他免疫细胞的招募/激活.
巨细胞具有有利的安全性和固体瘤中的持久性,这表明CAR-Ms可能比CAR-T细胞更安全,更持久.

结论:

CAR巨体代表了癌症免疫疗法的新和有前途的方法,利用具有CAR特性的巨体特性.
CAR-Ms有可能克服CAR-T细胞疗法的当前局限性,特别是在固体瘤中.
进一步开发CAR-M疗法可能会彻底改变细胞免疫疗法,并导致更有效,更可持续的癌症治疗.

关键词:

通过CAR-M治疗治疗.仿制性抗原受体的复制性受体.巨细胞是一个巨细胞.固体瘤是一个固体瘤.瘤免疫疗法免疫疗法

更多相关视频

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Published on: March 18, 2020

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cell-mediated Immune Responses

Cell-mediated Immune Responses

Immune Surveillance by NK Cells and Phagocytes

Immune Surveillance by NK Cells and Phagocytes

Immune surveillance is an integral part of the innate immune system, involving the continuous monitoring of peripheral tissues to detect and respond to pathogens, infected cells, or cancerous cells. This surveillance is conducted primarily by natural killer (NK) cells and phagocytes, which employ distinct but complementary mechanisms to identify and eliminate threats.
Natural Killer Cells: The Fast Responders
NK cells are large granular lymphocytes found in the blood and lymphatic system. These...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...